ATE400653T1 - Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen - Google Patents

Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen

Info

Publication number
ATE400653T1
ATE400653T1 AT96925537T AT96925537T ATE400653T1 AT E400653 T1 ATE400653 T1 AT E400653T1 AT 96925537 T AT96925537 T AT 96925537T AT 96925537 T AT96925537 T AT 96925537T AT E400653 T1 ATE400653 T1 AT E400653T1
Authority
AT
Austria
Prior art keywords
receptors
compounds
activity
metabotropic glutamate
metabotropic
Prior art date
Application number
AT96925537T
Other languages
English (en)
Inventor
Forrest H Fuller
Karen J Krapcho
Lance G Hammerland
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE400653T1 publication Critical patent/ATE400653T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96925537T 1995-07-26 1996-07-25 Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen ATE400653T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US152695P 1995-07-26 1995-07-26

Publications (1)

Publication Number Publication Date
ATE400653T1 true ATE400653T1 (de) 2008-07-15

Family

ID=21696494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96925537T ATE400653T1 (de) 1995-07-26 1996-07-25 Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen

Country Status (10)

Country Link
US (3) US5981195A (de)
EP (1) EP0783577B1 (de)
JP (2) JPH10507934A (de)
AT (1) ATE400653T1 (de)
AU (1) AU710128B2 (de)
CA (1) CA2200606A1 (de)
DE (1) DE69637587D1 (de)
ES (1) ES2308779T3 (de)
IL (2) IL120424A0 (de)
WO (1) WO1997005252A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU750179B2 (en) * 1995-07-26 2002-07-11 Astrazeneca Ab Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
ES2308779T3 (es) * 1995-07-26 2008-12-01 Astrazeneca Ab Receptores quimericos y metodos para identificar compuestos activos en los receptores de glutamato metabotropico y el uso de tales compuestos en el tratamiento de trastornos y enfermedades neurologicas.
US6084084A (en) * 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
WO1999021992A2 (en) * 1997-10-23 1999-05-06 Ganimed Pharmaceuticals Gmbh Nucleic acid molecules encoding a glutamate receptor
JP2002510480A (ja) * 1998-04-03 2002-04-09 エヌピーエス ファーマシューティカルズ インコーポレーテッド Ｇ−蛋白融合受容体およびキメラｇａｂａｂ受容体
US7262280B1 (en) 1998-04-03 2007-08-28 Nps Pharmaceuticals, Inc. G-protein fusion receptors and constructs encoding same
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
DK1196397T3 (da) 1999-06-02 2006-01-02 Nps Pharma Inc Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
US6534287B1 (en) 1999-10-25 2003-03-18 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
EP1257579B1 (de) * 2000-02-04 2009-08-05 Lexicon Pharmaceuticals, Inc. Neue menschliche g-protein gekoppelten rezeptoren und dafür kodierende polynucleotide
WO2001072842A2 (en) * 2000-03-28 2001-10-04 Lexicon Genetics Incorporated Human 7-transmembrane proteins and polynucleotides encoding the same
CA2416683A1 (en) 2000-07-21 2002-01-31 Merck & Co., Inc. Dog melanin-concentrating hormone receptor
CA2424546A1 (en) * 2000-10-03 2002-04-11 Nps Pharmaceuticals, Inc. G-protein fusion receptors and chimeric gabab receptors
BR0116420A (pt) * 2000-12-22 2006-02-21 Wyeth Corp proteìnas moduladoras de receptores de glutamato e moléculas de ácidos nucléicos e aplicações das mesmas
US20100248268A1 (en) * 2001-03-27 2010-09-30 Woods Daniel F Methods to utilize invertebrate chemosensory proteins for industrial and commercial uses
US20070003980A1 (en) * 2001-03-27 2007-01-04 Woods Daniel F Efficient methods to isolate effectors of proteins involved in olfactory or chemosensory pathways and efficient methods to use these effectors to alter organism olfaction, chemosensation, or behavior
WO2002097394A2 (en) 2001-05-31 2002-12-05 Merck & Co., Inc. Rhesus monkey, dog and ferret melanin-concentrating hormone type 2 receptor
WO2003035873A1 (en) 2001-10-23 2003-05-01 Ajinomoto Co, Inc Novel glutamic acid receptor and utilization thereof
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
CA2491946C (en) 2002-07-23 2013-05-28 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Ghrelin analogs
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US20050186658A1 (en) * 2003-10-17 2005-08-25 Nps Pharmaceuticals, Inc. Chimeric metabotropic glutamate receptors and uses thereof
CA2625447C (en) 2005-09-29 2015-06-09 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Compositions and methods for stimulating gastrointestinal motility
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
EP3029063B1 (de) * 2011-06-24 2019-10-16 Arctos Medical AG Chimäres lichtempfindliches gpgr-protein
WO2013120082A1 (en) 2012-02-10 2013-08-15 Kassab Ghassan S Methods and uses of biological tissues for various stent and other medical applications
EP4215163A1 (de) 2013-02-11 2023-07-26 Cook Medical Technologies LLC Expandierbarer stützrahmen und medizinische vorrichtung
EP3612210A4 (de) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System Manipulierte antigenrezeptoren exprimierende immunzellen
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
CN114729009A (zh) 2019-10-31 2022-07-08 伯尔尼大学 用于眼部基因递送的aav载体变体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
NZ240921A (en) * 1990-12-12 1994-06-27 Zymogenetics Inc G protein coupled glutamate receptor (neurotransmitters), recombinant production
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
CA2094987A1 (en) * 1992-05-01 1993-11-02 James P. Burnett, Jr. Human glutamate receptor proteins and associated dna compounds
IL105587A0 (en) * 1992-05-08 1993-09-22 Lilly Co Eli Human metabotropic glutamate receptor and related dna compounds
DE69333527T2 (de) * 1993-02-23 2005-06-16 Brigham & Women's Hospital, Inc., Boston Calciumrezeptoraktive moleküle
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
AU695641B2 (en) * 1993-09-20 1998-08-20 Novartis Ag Human metabotropic glutamate receptor subtypes (HMR4, HMR6, HMR7) and related DNA compounds
ES2285707T3 (es) * 1994-10-21 2007-11-16 Nps Pharmaceuticals, Inc. Compuestos activos frente al receptor de calcio.
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
ES2308779T3 (es) * 1995-07-26 2008-12-01 Astrazeneca Ab Receptores quimericos y metodos para identificar compuestos activos en los receptores de glutamato metabotropico y el uso de tales compuestos en el tratamiento de trastornos y enfermedades neurologicas.
US6084084A (en) * 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
US6288610B1 (en) * 1998-03-19 2001-09-11 Fujitsu Limited Method and apparatus for correcting signals, apparatus for compensating for distortion, apparatus for preparing distortion compensating data, and transmitter
BR0116420A (pt) * 2000-12-22 2006-02-21 Wyeth Corp proteìnas moduladoras de receptores de glutamato e moléculas de ácidos nucléicos e aplicações das mesmas
BE1014570A4 (fr) * 2002-01-11 2004-01-13 Sonaca Sa Procede de fabrication d'une structure cannelee et structure obtenue par ce procede.

Also Published As

Publication number Publication date
US5981195A (en) 1999-11-09
EP0783577B1 (de) 2008-07-09
US6534289B1 (en) 2003-03-18
AU710128B2 (en) 1999-09-16
ES2308779T3 (es) 2008-12-01
US20030113873A1 (en) 2003-06-19
JPH10507934A (ja) 1998-08-04
IL120424A (en) 2008-12-29
CA2200606A1 (en) 1997-02-13
JP2007006893A (ja) 2007-01-18
IL120424A0 (en) 1997-07-13
DE69637587D1 (de) 2008-08-21
WO1997005252A2 (en) 1997-02-13
EP0783577A1 (de) 1997-07-16
WO1997005252A3 (en) 1997-05-22
AU6602296A (en) 1997-02-26

Similar Documents

Publication Publication Date Title
ATE400653T1 (de) Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69535498D1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
ATE58299T1 (de) Geraet zur behandlung neurovegetativer stoerungen.
DE69611251D1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69632743D1 (de) Verfahren zur regulierung des vagaltonus
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE403437T1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
DE69617235D1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE60022050T2 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
ATE315230T1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE60023493D1 (de) Verwendung von synthetischen FXR Liganden zur Behandlung von Krankheiten die mit einem gestörten Gleichgewicht des Cholesterin-Spiegels verbunden sind und von Kolonkrebs
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE408840T1 (de) Verfahren zur identifizierung von agenzien zur behandlung von anfällen, neurologischen erkrankungen, endokrinopathien und hormonalen erkrankungen
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
ATE368110T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE60140074D1 (de) Non-apoptotische formen des zelltods und verfahren zur modulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties